Protocol Ledger

NCT06629779 · Phase III · RECRUITING

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Interventional Phase III clinical trial protocol NCT06629779 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-22 Enrollment: 900 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06629779
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)900 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06629779
Protocol FieldVerified Registry Value
NCT IdentifierNCT06629779
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment900 participants (ESTIMATED)
Registered Start Date2024-10-22
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI